105
Views
15
CrossRef citations to date
0
Altmetric
Review

Cost–effectiveness of rotavirus vaccines

&
Pages 593-601 | Published online: 09 Jan 2014

References

  • Parashar U, Hummelman E, Bresee J, Miller M, Glass R. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis. 9, 565–572 (2003).
  • Andersson N, Paredes S, Legorreta J, Ledogar RJ. Who pays for measles? The economic arguments for sustained immunization. Health Policy Plan. 7(4), 352–363 (1992).
  • Phillips MA, Feachem RG, Mills A. Options for diarrhoea control: the cost and cost–effectiveness of selected interventions for the prevention of diarrhoea. London School of Hygiene and Tropical Medicine, London, UK (1987).
  • Word Health Organization. Report of the meeting on future directions for rotavirus vaccine research in developing countries. World Health Organization, Department of Vaccines and Biologicals, Geneva, Switzerland (2000).
  • Cunliffe NA, Bresee JS, Hart CA. Rotavirus vaccines: development, current issues and future prospects. J. Infect. 45, 1–9 (2002).
  • Perez-Schael I. The impact of rotavirus disease in Venezuela. J. Infect. Dis. 174(Suppl. 1), S19–S21 (1996).
  • De Vos B, Vesikari T, Linhares A et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 23, S179–S182 (2004).
  • Clark HF, Bernstein DI, Dennehy PH et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J. Pediatr. 144, 184–190 (2004).
  • Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar U, Rheingans R. Projected cost–effectiveness of rotavirus vaccination of children in Asia. J. Infect. Dis. 192(Suppl. 1), 133–145 (2005).
  • Beutels P, Edmunds J, Antonanzas F et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. PharmacoEconomics 20, 1–7 (2002).
  • Brinsmead R, Hill S, Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediatr. Infect. Dis. J. 23, 32–37 (2004).
  • Kou U. Guidelines for estimating costs of introducing new vaccines into the national immunization system. World Health Organization, Department of Vaccines and Biologicals, Geneva, Switzerland (2002).
  • Carlin JB, Jackson T, Lane L, Bishop RF, Barnes GL. Cost effectiveness of rotavirus vaccination in Australia. Aust. NZ J. Public Health 23(6), 611–616 (1999).
  • Takala AK, Koskenniemi E, Joensuu J, Makela M, Vesikari T. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin. Infect. Dis. 27(2), 272–282 (1998).
  • Griffiths RI, Anderson GF, Powe NR et al. Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial. Arch. Pediatr. Adolesc. Med. 149(4), 407–414 (1995).
  • Smith JC, Haddix JC, Teutsch SM, Glass RI. Cost–effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 96(4 Pt 1), 609–615 (1995).
  • Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost–effectiveness analysis of a rotavirus immunization program for the United States. JAMA 279(17), 1371–1376 (1998).
  • Ehrenkranz P, Lanata CF, Penny ME, Salazar-Lindo E, Glass RI. Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev. Panam. Salud Publica 10, 240–248 (2001).
  • Miller M, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type b, Streptococcus pneumoniae conjugate and rotavirus vaccines in national immunization schedules. Health Econ. 9, 19–35 (2000).
  • Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies. Health Econ. 10, 751–774 (2001).
  • Jamison D, Mosley W, Measham A, Bobadilla J. Disease Control Priorities in Developing Countries. Oxford University Press, NY, USA (1993).
  • Garber AM, Phelps CE. Economic foundations of cost–effectiveness analysis. J. Health Econ. 16, 1–31 (1997).
  • England S, Loevinsohn B, Melgaard B, Kou U, Jha P. The evidence base for interventions to reduce mortality from vaccine-preventable diseases in low and middle-income countries. CMH Working Paper Series, number 10, Commission on Macroeconomics and Health, World Health Organization, Geneva, Switzerland (2001).
  • Griffiths U, Rheingans R, Walker D. Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the impact of rotavirus diarrhoea. World Health Organization, Department of Vaccines and Biologicals, Geneva, Switzerland (2005) (In Press)
  • Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele, AD. Rotavirus vaccines: targeting the developing world. J. Infect. Dis. 192(Suppl. 1), 160–166 (2005).
  • Wecker J. Costs of a rotavirus vaccine. Science 307, 517–519 (2005).

Websites

  • Rotavirus Vaccine Program www.rotavirusvaccine.org (Accessed September 2005)
  • WHO CHOICE: Choosing interventions that are cost effective www3.who.int/whosis/menu.cfm?path = whosis,evidence,cea&language = English (Accessed September 2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.